핵심요약

• 모더나 주가는 연초 이후 100% 이상 급등
• CMV 백신 후보물질이 3상 시험에서 실패
• 8월 5일까지 긍정적인 소식이 기대됨
• mRNA 기술로 코로나19 백신과 RSV 백신 승인 획득

도입

모더나 주식의 최근 급등은 투자자들에게 중요한 신호를 보내고 있습니다. 특히 8월 5일까지 확인될 긍정적인 소식이 주목받고 있으며, 이는 장기적인 성장 가능성을 평가하는 데 중요한 기준이 될 수 있습니다. 또한, mRNA 기술의 효능이 입증되면서 모더나의 기술력에 대한 신뢰도가 높아지고 있습니다.

본문 1: mRNA 기술의 시장 반응

모더나 주가가 100% 이상 급등한 배경에는 mRNA 기술의 시장 반응이 있습니다. 특히 코로나19 백신과 RSV 백신 승인을 통해 mRNA 기술의 효능이 입증되면서 투자자들의 관심이 높아지고 있습니다. 이는 모더나의 기술력에 대한 신뢰도를 높이는 요인이 되었습니다. 또한, mRNA 기술이 다양한 질병에 적용될 수 있는 가능성을 보여주면서 장기적인 성장 전망이 밝아지고 있습니다.

본문 2: CMV 백신 실패의 영향

CMV 백신 후보물질이 3상 시험에서 실패한 것은 모더나에게 큰 타격으로 작용했습니다. CMV 백신은 블록버스터급 성공이 예상되었지만, 실패로 인해 모더나의 수익성 전망이 어두워졌습니다. 그러나 이는 모더나만의 문제가 아니라, 모든 바이오테크와 제약회사들이 직면하는 리스크 중 하나입니다. 따라서 CMV 백신 실패가 모더나의 장기적인 성장 story를 크게 흔들지는 않을 것입니다.

본문 3: 8월 5일까지의 기대감

8월 5일까지 긍정적인 소식이 기대되는 것은 모더나 주식에 대한 투자자들의 관심을 높이고 있습니다. 이 소식이 어떤 내용인지에 따라 모더나의 주가 변동성이 커질 수 있습니다. 그러나 긍정적인 소식이 확인되면 모더나의 기술력과 성장 가능성에 대한 신뢰도가 더욱 높아질 가능성이 있습니다. 따라서 8월 5일을 전후하여 모더나 주식의 움직임을 주의 깊게 지켜볼 필요가 있습니다.

결론

모더나의 mRNA 기술은 코로나19 백신과 RSV 백신 승인을 통해 그 효능을 입증했습니다. 그러나 CMV 백신 실패와 같은 리스크도 존재하므로, 장기적인 성장 가능성을 평가할 때 다양한 요인을 고려해야 합니다. 8월 5일까지의 긍정적인 소식이 확인되면 모더나의 주가 변동성이 커질 수 있으므로, 투자자들은 신중한 판단이 필요합니다.

---

원문 링크: https://www.fool.com/investing/2026/06/22/should-you-buy-moderna-before-aug-5/?.tsrc=rss

Should You Buy Moderna Before Aug. 5?

Moderna ( MRNA 7.21% ) stock skyrocketed in early pandemic days -- and the company became a household name -- as it launched its coronavirus vaccine. This first product, and one using the new messenger RNA technology, brought in billions of dollars in revenue and proved the efficacy of mRNA.

But in recent years, as demand for the vaccine declined, Moderna's earnings followed. The company suffered various setbacks, such as the failure of its cytomegalovirus (CMV) vaccine candidate in late-stage trials, and investors no longer rushed to get in on this biotech stock.

Things may be turning around for Moderna, though: The stock has soared more than 100% since the start of the year. And just recently, the company announced positive news -- to be confirmed on or before Aug. 5. Should you buy Moderna stock before that date? Let's find out.

So first, let's take a quick look at the Moderna story and strategy. As mentioned, the company took center stage during early pandemic days, thanks to its coronavirus vaccine. Moderna uses mRNA in this product and throughout its pipeline, and it works by teaching the body to make proteins to fight off a particular virus or disease.

The coronavirus approval offered Moderna the opportunity to prove that this technique works -- and Moderna went on to win approval for a respiratory syncytial virus (RSV) vaccine and a second coronavirus vaccine.

Meanwhile, the company continued shepherding other candidates through the pipeline -- from respiratory and latent virus vaccine candidates to investigational oncology and rare disease therapeutics. Moderna suffered setbacks in recent years, from RSV vaccine sales coming in lower than expected to the failure of its CMV candidate -- one that was expected to become a blockbuster -- in a phase 3 trial.

But setbacks are part of the story for all biotech and pharma companies and don't necessarily alter the long-term growth story. In this case, the failures don't call into question Moderna's mRNA technology, and the company's pipeline is strong, with many promising candidates. All of this is positive.

Three potential product launches

In fact, Moderna is gearing up for potential product launches in the coming years. The biotech aims to release three, including a combination flu and coronavirus vaccine , and seasonal flu and norovirus vaccines, over 2027 and 2028. The company says late-stage data from rare disease and oncology trials may also lead to launches in those areas just ahead. So Moderna may be at a key transition point right now, and investors have recognized this, as we can see through the stock price performance since the start of the year.

Now, let's consider what's about to unfold on or just before Aug. 5. It has to do with the company's investigational flu vaccine candidate, mRNA-1010. A U.S. Food and Drug Administration advisory panel voted unanimously in favor of the candidate, a vote that the benefits outweigh the risks. The independent committee voted in favor for the 50 to 64 age group and the 65-and-older age group.

Now, the FDA has a deadline of Aug. 5 to issue a decision regarding the vaccine. Though the regulatory agency doesn't have to follow the recommendation of the committee, it generally does -- so there is reason for investors to be optimistic about what might unfold. And this puts Moderna's flu candidate on track to launch for the 2026-2027 flu season.

Does all of this make Moderna a buy today? Moderna clearly has reached a key turning point, with many potential revenue drivers ahead, and that makes now a great time to be a shareholder. It's important to keep in mind that some risk is involved. Even if Moderna wins approval of its flu vaccine, soaring sales may not happen overnight. Still, this would be a critical step forward for the company as it builds out its presence as a multi-product commercial-stage biotech.

Moderna stock has climbed quite a bit this year, so a lot of the good news could be priced in at today's levels. A potential flu vaccine approval may result in a pop for the stock price, but I don't think gains will continue on uninterrupted. There may be opportunities in the near future and after Aug. 5 to buy Moderna on the dip -- and that's when growth investors should make the move.

Source: https://www.fool.com/investing/2026/06/22/should-you-buy-moderna-before-aug-5/?.tsrc=rss